MindMed is a psychedelic medicine biotech company that studies how shrooms, LSD, and even MDMA and DMT can help treat depression. Honestly, I already confirmed their studies to be true in college. Anyways, MindMed has been trading OTC in like Canada's market or something (I guess there are companies that exist outside the USA) so only brokers ...

2023年4月7日 · While I mostly agree with this (not the condescending part), this should end up positive and massive. Most of the people in this reddit stream have used the real thing at some time or another for the health benefits, and can attest to the positive results anecdotally.

2021年1月1日 · MindMed (MMED.F) was mentioned a ton of times a few weeks ago and pumped all the way to $6 a share (from <$1 a few months ag). Then they announced they were raising money and diluting shares and the stock dropped a lot, now settling at $3. Are you still holding? I know there was a lot of hype of whether they'd be added to the NASDAQ.

2022年8月11日 · FCM contends that MindMed can bring MM-120 to market in four years rather than seven to eight years, by re-classifying MindMed’s Phase IIb study on MM-120 to a Phase III study. FCM also proposes that the Company reduce costs from forty-five million dollars per year to under twenty-five million dollars and that the unnecessary and dilutive at ...

Over the past month, while FCM has provided MindMed’s Management (“Management”) with a comprehensive understanding of FCM’s Value Enhancement Plan (see mindmed.zone/letter), Management has consistently “slow rolled” the negotiations, misled FCM regarding timelines, and engaged in bad faith antics while the stock has continued its ...

2021年2月16日 · MindMed maintains approximately $144.7M in cash on hand. 10. MindMed has at least five known catalysts expected to occur this year, including a Nasdaq listing that is imminent. 11. MindMed has six medications and treatment protocols currently in clinical trials, including treatments for opioid addiction, depression, anxiety, and headaches. 12.

2022年3月11日 · August 4 2022 - mindmed board of directors approves 15:1 reverse split In conclusion, my read of the landscape here is that mindmed is in dire straits in terms of drug development. Its core leadership has bailed, the US government has chosen an alternative company with whom to collab on ibogaine, and its remaining programs are in LSD, which is ...

MindMed results were extremely positive - 50% remission in a large Phase 2b trial. Now moving to Phase 3 with more solid data to support the company's proposal to the FDA. Where are the Freeman supporters saying MindMed management didn't know what they were doing?

2021年1月13日 · #1 - MindMed has not filed form 40-F with the SEC. The Form 40-F is an annual form required for all companies trading on the Nasdaq. Any company that has been trading publicly for less than 12 months cannot file the 40-F. In other words, MindMed cannot submit this form until after March 3rd, and is not in any way tied to the Nasdaq approval.

MindMed is waiting for approval of a Nasdaq uplisting, which I assume will impact value. I’ve already made good money off of this, and they’re just getting started. Please do dig in further to satisfy your curiosity, they’re backed by Kevin O’Leary (SharkTank), Bruce Linton (founder of Canopy Growth), and the founder of Tom’s Shoes ...